Clinical trials: Migraine with Aura
Migraine
Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.
- Trial name
- NCT02472418
- Testing
- DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B)
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine Without Aura
Migraine STImulation Crisis of Migraine
Migraine is a neurovascular disease whose prevalence is estimated at almost 20% of the adult population. Currently, there is no treatment for migraine.
- Trial name
- MISTIC (NCT04568252)
- Testing
- Wristband with millimeter wave emission.
- Where
- 6 sites in France
- Volunteers
- 140 people
- Sponsor
- Remedee SA
Migraine
A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine
This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.
- Trial name
- MONONOFU (NCT03962738)
- Testing
- Lasmiditan
- Where
- 34 sites in Japan
- Volunteers
- 846 people
- Sponsor
- Eli Lilly and Company
Migraine With or Without Aura
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
A previously published, placebo-controlled, head-to-head comparator study found eletriptan to have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack.
- Trial name
- NCT01986088
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg, Sumatriptan 50 mg
- Volunteers
- 1,008 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, Common Migraine
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg taken daily) compared with placebo in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00236509
- Testing
- topiramate
- Volunteers
- 763 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine With or Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT03061734)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine, Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.
- Conditions
- Migraine, Pain, Nausea, Vomiting
- Trial name
- NCT03877718
- Testing
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule
- Where
- 3 sites in United States
- Volunteers
- 475 people
- Sponsor
- Charleston Laboratories, Inc
Migraine
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)
The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants.
- Trial name
- NCT00443209
- Testing
- Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets
- Volunteers
- 1,068 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00382993
- Testing
- Combination Product (sumatriptan succinate/naproxen sodium)
- Where
- 28 sites in United States
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
Migraine, With or Without Aura
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
- Trial name
- NCT02873221
- Testing
- Ubrogepant, Usual Care
- Where
- 177 sites in United States
- Volunteers
- 1,254 people
- Sponsor
- Allergan
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Migraine
A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)
This study will test the safety and how effective telcagepant is when taken with ibuprofen or acetaminophen in participants with migraine with or without aura.
- Trial name
- NCT00758836
- Testing
- ibuprofen, acetominophen, telcagepant
- Volunteers
- 683 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine With Aura, Migraine Without Aura
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT03874832
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories
Migraine, With or Without Aura
Open Label Safety Study in Acute Treatment of Migraine
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
- Trial name
- NCT03266588
- Testing
- Rimegepant
- Where
- 98 sites in United States
- Volunteers
- 3,019 people
- Sponsor
- Pfizer
Migraine Disorders
Migraine Study in Adolescent Patients
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
- Trial name
- NCT00843024
- Testing
- Sumatriptan and Naproxen Sodium
- Where
- 79 sites in United States
- Volunteers
- 589 people
- Sponsor
- GlaxoSmithKline
Episodic Migraine
DFN-11 Injection in Episodic Migraine With or Without Aura
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
- Trial name
- RESTOR (NCT02569853)
- Testing
- DFN-11
- Where
- 16 sites in United States
- Volunteers
- 268 people
- Sponsor
- Dr. Reddy's Laboratories Limited